FDA Expands Safety Signal Assessment With Mechanism-Based System
This article was originally published in The Pink Sheet Daily
FDA will work with MolecularHealth Inc. to adapt the company’s software system, which combines molecular data with clinical data, to allow mechanism-based assessment of side effects.
You may also be interested in...
With the recent addition of claims data from two major insurance companies, the FDA postmarketing drug safety surveillance pilot project known as Mini Sentinel has already exceeded its statutory goal of gaining access to electronic health care data for 100 million individuals by July 12, 2012.
U.S. and European regulations expect qualification of biomarkers for clinical use to be a multi-stage process that incrementally broadens a marker's application
Combination of new science and technology could allow drug developers to identify molecular risk targets, much as they look for therapeutic targets, agency tells advisory panel.